FDA Brief

Warning letters Drugs

FDA warning letter to

Gulf States International, Inc.

MediumIssued Sep 12, 2023Posted Sep 26, 2023Center for Drug Evaluation and Research | CDER

Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

What happened

FDA sent electronic requests for records on September 9 and September 27, 2022, to the email address in the company’s drug registration file. The company acknowledged the request on October 3, 2022, but did not provide the records, and FDA said phone messages on November 16, 2022, and September 6, 2023, also went unanswered. FDA said it therefore has no indication of the quality assurance for drugs registered as manufactured at the facility.

What FDA found

  1. The company refused to let FDA access or copy records the agency requested about its OTC drug manufacturing, which the Federal Food, Drug, and Cosmetic Act prohibits.

    Section 301(e) of the FD&C Act (21 U.S.C. 331(e)); section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))

What FDA wants

FDA tells the company to respond within 48 hours to confirm or update its drug registration and listing status and to say whether it will provide the requested records. If it no longer makes drugs, FDA says it must delist all previously listed drugs and deregister the facility.

Who should pay attention

  • brands that buy OTC drug products from this manufacturer
  • companies using the same contract manufacturer
  • quality teams responsible for FDA registration and records requests

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  4. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk